Cadre Holdings, Inc. (CDRE)

Oncternal Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	572.61	567.56	482.53	457.84	427.29	404.64
Revenue Growth (YoY)	7.66%	17.62%	5.39%	7.15%	5.60%	-3.82%
Cost of Revenue	333.12	330.22	281.81	277.9	256.6	251.7
Gross Profit	239.49	237.34	200.73	179.93	170.69	152.94
Selling, General & Admin	166.59	158.96	141.02	153.61	115.54	108.26
Other Operating Expenses	-	-	-	-	-	0.02
Operating Expenses	166.59	158.96	141.02	153.61	115.54	108.28
Operating Income	72.9	78.38	59.71	26.33	55.15	44.66
Interest Expense	-10	-7.82	-4.53	-6.21	-16.43	-24.39
Currency Exchange Gain (Loss)	4.46	-4.72	0.94	-	-0.95	-
Other Non Operating Income (Expenses)	-	-	-	-1.14	-	0.45
EBT Excluding Unusual Items	67.35	65.83	56.12	18.98	37.78	20.71
Merger & Restructuring Charges	-9.83	-11.62	-3.19	-9.61	-3.43	-0.16
Gain (Loss) on Sale of Investments	-	-	-	-	-	6.94
Gain (Loss) on Sale of Assets	-	-	-	-	-	6.24
Other Unusual Items	-	-	-	-	-15.16	-5.86
Pretax Income	57.52	54.22	52.92	9.37	19.19	27.88
Income Tax Expense	19.43	18.09	14.28	3.55	6.53	-10.58
Net Income	38.1	36.13	38.64	5.82	12.66	38.45
Net Income to Common	38.1	36.13	38.64	5.82	12.66	38.45
Net Income Growth	-5.09%	-6.49%	563.94%	-54.03%	-67.07%	-
Shares Outstanding (Basic)	41	40	38	36	29	27
Shares Outstanding (Diluted)	41	40	38	36	29	27
Shares Change (YoY)	5.32%	6.36%	4.98%	26.31%	4.06%	0.30%
EPS (Basic)	0.94	0.90	1.03	0.16	0.44	1.40
EPS (Diluted)	0.93	0.90	1.02	0.16	0.44	1.40
EPS Growth	-9.48%	-11.77%	537.50%	-63.64%	-68.55%	-
Free Cash Flow	33.44	26.11	66.48	41.92	37.26	40.71
Free Cash Flow Per Share	0.82	0.65	1.75	1.16	1.30	1.48
Dividend Per Share	0.365	0.350	0.320	0.320	0.080	-
Dividend Growth	8.96%	9.38%	-	300.00%	-	-
Gross Margin	41.82%	41.82%	41.60%	39.30%	39.95%	37.80%
Operating Margin	12.73%	13.81%	12.38%	5.75%	12.91%	11.04%
Profit Margin	6.65%	6.37%	8.01%	1.27%	2.96%	9.50%
Free Cash Flow Margin	5.84%	4.60%	13.78%	9.16%	8.72%	10.06%
EBITDA	89.29	94.8	75.45	41.98	68.87	59.39
EBITDA Margin	15.59%	16.70%	15.64%	9.17%	16.12%	14.68%
D&A For EBITDA	16.39	16.42	15.74	15.65	13.72	14.73
EBIT	72.9	78.38	59.71	26.33	55.15	44.66
EBIT Margin	12.73%	13.81%	12.38%	5.75%	12.91%	11.04%
Effective Tax Rate	33.77%	33.36%	26.99%	37.91%	34.03%	-

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q